Asthma therapeutic development by theophylline complex in nano-scale

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

Asthma is one of the most common inflammatory disorders in all ages and cultures. Asthma affects all people. It is a chronic disease caused by airway blockage in the lungs. Characteristics of asthma include wheezing, tightness of the chest, and respiratory problems. Clinical signs and symptoms are used to diagnose asthma. In asthma patients with asthma, phosphodiesterase PDEs typically split off phosphorous groups and decrease cyclic Adenosine monophosphate cAMP or cyclic guanosine monophosphate cGMP in target cells. The amount of serum PDE increases in the cyclic extracellular nucleotides. ln this book, we review A novel synthesis-therapy in nanoscale for asthma patients by inhibits phosphodiesterase enzyme.